Head-to-head evidence
BIIB091 vs Tolebrutinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: Bruton's tyrosine kinase (BTK) · full Multiple Sclerosis pipeline
BIIB091
Developed by Biogen
NCT05798520 · Phase 2 · completed
The study randomized 127 participants and used quadruple blinding with active and matching-placebo comparator arms. Its primary outcomes included adverse events and new MRI lesions, but no results or statistical comparison have been posted, so the primary endpoint cannot be judged as met or missed.
Tolebrutinib
Developed by Sanofi
NCT04411641 · Phase 3 · completed
The trial randomized 1,131 participants in a 2:1 ratio to double-blind tolebrutinib or matching placebo, with participants, investigators, and outcome assessors masked. Its primary clinical endpoint—6-month confirmed disability progression measured by EDSS—was statistically met, with a hazard ratio of 0.693 (95% CI 0.546–0.880; p=0.0026).
Next expected readout: April 2029 · NCT06372145 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BIIB091's landscape · Tolebrutinib's landscape